Boehringer Ingelheim and Brainomix are expanding their collaboration on an AI tool aimed at diagnosing interstitial lung diseases (ILDs) with a new prospective clinical trial.
The partnership, which began in 2024, focuses on utilizing Brainomix's e-Lung software to enhance the diagnosis of conditions like progressive pulmonary fibrosis (PPF). The findings from a retrospective study, REVISE-PPF, will be presented at an upcoming conference, showcasing how e-Lung analyzed historical CT scans to identify subtle indicators of ILDs. This analysis indicated that the software could potentially reduce diagnosis times for PPF by over two years compared to traditional methods.
Building on these results, the upcoming PROGRESS-PPF study will assess the effectiveness of e-Lung in real-time clinical settings across various pulmonary care facilities in the U.S. The goal is to determine if routine application of this FDA-approved software can facilitate earlier diagnoses, thereby allowing for earlier treatment interventions that could enhance patient outcomes.
Given that untreated PPF can significantly shorten patient lifespan, early detection is crucial. Boehringer Ingelheim's existing treatments for idiopathic pulmonary fibrosis, such as Ofev and the recently approved Jascayd, underscore the importance of timely diagnosis. Dr. Michalis Papadakis of Brainomix emphasized the compelling evidence supporting e-Lung's capability to expedite diagnosis, suggesting that this next phase could validate its transformative potential in patient care pathways.